News
AZ/Daiichi Sankyo’s datopotamab deruxtecan demonstrates ‘promising’ early results in TNBC
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ACD) datopotamab deruxtecan has demonstrated ‘promising’ preliminary response and disease control in new data evaluating the therapy among patients with metastatic triple negative breast cancer (TNBC).